| Identification | Back Directory | [Name]
Butanamide, 2-[(2-amino-9H-purin-6-yl)thio]-N-(4-hydroxy-3-methoxyphenyl)- | [CAS]
2631703-41-6 | [Synonyms]
Butanamide, 2-[(2-amino-9H-purin-6-yl)thio]-N-(4-hydroxy-3-methoxyphenyl)- | [Molecular Formula]
C16H18N6O3S | [MOL File]
2631703-41-6.mol | [Molecular Weight]
374.42 |
| Chemical Properties | Back Directory | [density ]
1.50±0.1 g/cm3(Predicted) | [solubility ]
DMSO: 1 mg/ml | [form ]
A crystalline solid | [pka]
9.24±0.10(Predicted) | [color ]
Off-white to gray |
| Hazard Information | Back Directory | [Description]
ENPP1 inhibitor 43 is an inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1; Ki = 41 nM).1 It inhibits tumor growth in an LLC1 murine lung cancer model when administered orally or intravenously at doses of 10 and 100 mg/kg, respectively. | [Uses]
Enpp-1-IN-12 (compound 43) is a potent and orally active ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor, with a Ki of 41 nM. Enpp-1-IN-12 exhibits anti-tumor activity[1]. | [in vivo]
Enpp-1-IN-12 (100 mg/kg; p.o.) inhibits tumor growth in LLC1 syngeneic murine tumor model for lung cancer[1].
Enpp-1-IN-12 (10 mg/kg; p.o.) exhibits moderate oral bioavailability (F=45.1%), half-life (t1/2=1.04 h), and Cmax (303.10 ng/mL) in healthy female BALB/c mice[1].
Enpp-1-IN-12 (1 mg/kg; i.v.) exhibits half-life (t1/2=0.76 h), Cmax (308.64 ng/mL), and CL of 73.22 mL/min/kg in healthy female BALB/c mice[1]. | [References]
1. Gangar, M., Goyal, S., Raykar, D., et al. Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy Bioorg. Chem. 119,105549(2022). |
|
|